Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2436 • ACR Convergence 2023
Characterizing Spatial Organization of Immune Infiltrates in Rheumatoid Arthritis Synovia Using Spatial Transcriptomic Analysis
Roopa Madhu¹, Kartik Bhamidipati¹, Anna Helena Jonsson¹, Fan Zhang², Lucy MacDonald³, Youngmi Kim⁴, Yi Cui⁴, STARS BWH¹, Accelerating Medicines Partnership Program RA SLE Network⁵, Mariola Kurowska-Stolarska³, Stefano Alvernini⁶, Ellen Gravallese⁷, Michael Brenner⁷, Soumya Raychaudhuri¹, Kevin Wei⁷ and ilya Korsunsky¹, ¹Brigham and Women's Hospital, Boston, MA, ²University of Colorado, Aurora, CO, ³Research into Inflammatory Arthritis Centre Versus Arthritis (RACE), University of Glasgow, Glasgow, United Kingdom, ⁴Nanostring, Seattle, WA, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Division of Rheumatology, Università Cattolica del Sacro Cuore, Rome, Italy, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by immune infiltration of the synovial tissue lining joints. RA is clinically heterogenous, with patients having…
Abstract Number: 2533 • ACR Convergence 2023
Real-world Evidence for Assessing Mortality Disparity Between the Patients with Rheumatoid Arthritis and the General Population in Japan: Results from the IORRA Study
Naohiro Sugitani¹, Eiichi Tanaka², Eisuke Inoue³, Mai Abe¹, Eri Sugano¹, Kumiko Saka¹, Moeko Ochiai⁴, Rei Yamaguchi¹, Katsunori Ikari⁵, Ayako Nakajima⁶, Hisashi Yamanaka⁷ and Masayoshi Harigai⁸, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Shinjunku-ku, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Research Administration Center, Showa University, Shinagawa-ku, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine,, Shinjunku-ku, Japan, ⁵Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ⁶Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ⁷Sanno Medical Center, Tokyo, Japan, ⁸Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have been reported to have higher mortality rates than the general population. Our previous report showed that the standardized…
Abstract Number: PP08 • ACR Convergence 2023
Finding Gratitude in Adversity: The Impact of Finding the Right Rheumatologist
Yaideliz Acevedo, Global Healthy Living Foundation, Newark, NJ
Background/Purpose: I recall sitting in the doctor's office with my one-month-old baby in his stroller, hearing the words "You have rheumatoid arthritis." At 21, I…
Abstract Number: 0021 • ACR Convergence 2023
Shared Genetic Susceptibility Between Rheumatoid Arthritis and Bipolar Disorder: Analyses from Genome-Wide Association Studies
Jiayi Zheng¹, Ruoning Ni², Nevena Barjaktarovic³ and Yiming Luo⁴, ¹The Wright Center for Graduate Medical Education, Scranton, PA, ²University of Iowa Hospitals and Clinics, Coralville, IA, ³The Wright Center for Community Health, South Abington Township, PA, ⁴Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) has been associated with bipolar disorder (BD) in epidemiological studies, including a recent Mendelian randomization analysis. This study aims to prioritize…
Abstract Number: 0082 • ACR Convergence 2023
A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model
Adam Cartwright¹, Foram Desai², Sophia Nguyen², Alexandra Trouilloud², Elisa Liardo¹, Daric Wible², Ilaria Lamberto², Bradley Demarco², Chris King², Debora Bonenfant¹, Sharon Townson², Owen Wallace², Filip Janku², Laura McAllister¹, Alison Paterson² and Marisa Peluso², ¹Monte Rosa Therapeutics, Basel, Switzerland, ²Monte Rosa Therapeutics, Boston, MA
Background/Purpose: VAV1 is a member of the VAV family of guanine nucleotide exchange factors (GEFs) and plays a critical role in mediating T- and B-cell…
Abstract Number: 0218 • ACR Convergence 2023
Incidence and Risk Factors for Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients with Systemic Autoimmune Rheumatic Diseases
Yumeko Kawano¹, Xiaosong Wang¹, Naomi Patel², Grace Qian¹, Emily Kowalski¹, Katarina Bade³, Kathleen Vanni¹, Accelerating Medicines Partnership (AMP): RA/SLE¹, Zachary Williams², Claire Cook², Shruthi Srivatsan², Zachary Wallace⁴ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: During the height of the COVID-19 pandemic in the United States, tixagevimab/cilgavimab (Evusheld), a combination of monoclonal antibodies directed against the SARS-CoV2 spike protein,…
Abstract Number: 0384 • ACR Convergence 2023
Targeting NET Formation in Early RA Patients; A Spin-off Study from the NORD-STAR
Bas Dijkshoorn¹, Ting Wang², Gerdur Maria Grondal³, Daisy Vedder⁴, Anna Rudin⁵, Dan Nordstrom⁶, Bjorn Gudbjornsson⁷, Kristina Lend⁸, Till Uhlig⁹, Espen Haavardsholm⁹, Merete L Hetland¹⁰, Marte Schrumpf Heiberg¹¹, Mikkel Østergaard¹², Kim Horslev-Petersen¹³, John Lampa¹⁴, Ronald van Vollenhoven¹⁵, Christian Lood² and Michael Nurmohamed¹⁶, ¹Amsterdam Rheumatology and Immunology Center, Location Reade, Amsterdam, Netherlands, ²University of Washington, Seattle, WA, ³Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ⁴Reade, Amsterdam, Netherlands, ⁵Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Helsinki University Hospital, Helsinki, Finland, ⁷Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁸Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ⁹Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹⁰Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ¹¹Diakonhjemmet Hospital, Oslo, Norway, ¹²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ¹³Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ¹⁴Stockholm County, Hãsselby, Sweden, ¹⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹⁶Amsterdam University Medical Centers, Kortenhoef, Netherlands
Background/Purpose: The formation of neutrophil extracellular traps (NETs) with extrusion of nuclear, granular and cytosolic components from a dying neutrophil, has been described extensively in…
Abstract Number: 0400 • ACR Convergence 2023
Thresholds of Presenteeism Measurement Instruments for Unacceptable Work Participation and Future Adverse Work Outcomes in Rheumatoid Arthritis
Dafne Capelusnik¹, Sofia Ramiro², Elena Nikiphorou³, Walter P. Maksymowych⁴, Marina Nighat Magrey⁵, Helena Marzo-Ortega⁶ and Annelies Boonen⁷, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³King's College London, London, United Kingdom, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Case Western Reserve University, University Hospitals, Cleveland, OH, ⁶NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁷Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands
Background/Purpose: Presenteeism is associated with lower work satisfaction and increased risk of future sick leave in rheumatic diseases. It is generally measured on a continuous…
Abstract Number: 0417 • ACR Convergence 2023
The Role of Rheumatoid Arthritis Flare in the Risk of Alzheimer’s Disease and Related Dementias: A Population-based Cohort Study
Chanakya Kodishala¹, Tina Gunderson², Edward Lovering², Rakesh Kumar², Cynthia Crowson², John Davis² and Elena Myasoedova², ¹Mayo Clinic Rochester Minnesota, Rochester, MN, ²Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased risk for Alzheimer's disease and related dementias (AD/ADRD). Recent studies have reported an association between RA disease…
Abstract Number: 0434 • ACR Convergence 2023
Effects of B/tsDMARDs on Non-inflammatory Pain in Patients with Rheumatoid Arthritis -ANSWER Longitudinal Cohort Study-
Mai Yamashita¹, Takaichi Okano¹, Iku Shirasugi¹, Hirotaka Yamada¹, Keisuke Nishimura¹, Sho Sendo¹, Yo Ueda¹, Toshihisa Maeda², Shinya Hayashi², Wataru Yamamoto³, Akira Onishi⁴, Kosaku Murakami⁵, Hideyuki Shiba⁶, Kenichiro Hata⁶, Kohei Tsujimoto⁷, Kosuke Ebina⁸, Yonsu Son⁹, Naofumi Yoshida⁹, Ryota Hara¹⁰, Ryu Watanabe¹¹, Motomu Hashimoto¹¹, Ryosuke Kuroda² and Jun Saegusa¹, ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Japan, ⁴Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁶Department of Internal Medicine (Ⅳ), Osaka Medical and Pharmaceutical University, Takatsuki, Japan, ⁷Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Toyonaka, Osaka, Japan, ⁸Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, Toyonaka,Osaka, Japan, ⁹First Department of Internal Medicine, Kansai Medical University, Osaka, Hirakata, Japan, ¹⁰Department of Orthopaedic Surgery, Nara Medical University, Nara, Japan, ¹¹Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
Background/Purpose: Non-inflammatory pain (NIP) is one of the remaining issues in rheumatoid arthritis (RA), and some previous studies suggest that 10-20% of patients with RA…
Abstract Number: 0451 • ACR Convergence 2023
Long-term Clinical Profile of Filgotinib in Patients with Rheumatoid Arthritis by Cardiovascular Risk Factors: A Post Hoc Subgroup Analysis
Maya Buch¹, Jose A Gomez-Puerta², Gerd Burmester³, Bernard G. Combe⁴, Vijay Rajendran⁵, Pieter-Jan Stiers⁶, Paul Van Hoek⁷, Katrien Van Beneden⁷, Jacques-Eric Gottenberg⁸, Yoshiya Tanaka⁹, Daniel Aletaha¹⁰, René Westhovens¹¹ and Roberto F. Caporali¹², ¹University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ²Department of Rheumatology, Hospital Clinic of Barcelona, Barcelona, Spain, ³Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ⁴Department of Rheumatology, Montpellier University, Montpellier, France, ⁵Clinical Research, Galapagos NV, Mechelen, Belgium, ⁶Biostatistics, Galapagos NV, Mechelen, Belgium, ⁷Medical Safety, Galapagos NV, Mechelen, Belgium, ⁸Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ⁹University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria, ¹¹Department of Rheumatology, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ¹²Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy
Background/Purpose: Filgotinib (FIL) is an oral Janus kinase 1 preferential inhibitor for the treatment of moderate to severe active RA. A previous pooled analysis reported…
Abstract Number: 0636 • ACR Convergence 2023
Chasing Pain: Investigating Somatosensory Profiles in Patients with Rheumatological Diseases Using Quantitative Sensory Testing
Claus Juergen Bauer¹, Ruth Sophie Schrapper², Simon Petzinna³, Charlotte Behning⁴, Tim T.A. Bender⁵, Peter Brossart¹, Martin Muecke⁶ and Valentin Sebastian Schäfer¹, ¹Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, ²University of Bonn, Bonn, Germany, ³Clinic of Internal Medicine III, Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Bonn, Germany, ⁴Institute of Medical Biometry, Informatics and Epidemiology, University Hospital of Bonn, Bonn, Germany, ⁵University Hospital of Bonn, Bonn, Germany, ⁶Universital Hospital of Aachen, Aachen, Germany
Background/Purpose: Pain is a prominent symptom in numerous rheumatological diseases. In order to allow for a standardized quantification and the assessment of nociceptive and non-nociceptive…
Abstract Number: 0793 • ACR Convergence 2023
The Dual Specificity Phosphatase 6 (DUSP6) Regulates Arthritis Severity and IL10 Production
Teresina Laragione, Carolyn Harris, Natasha Rice and Percio Gulko, Icahn school of Medicine at Mount Sinai, New York, NY
Background/Purpose: We have previously identified the Huntingtin-interacting protein-1 (HIP1) as a new gene implicated in the regulation of the rheumatoid arthritis (RA) fibroblast-like synoviocyte (FLS)…
Abstract Number: 0838 • ACR Convergence 2023
Infusion of Etanercept into the Peripheral Lymphatics Significantly Reduces Disease Activity in Rheumatoid Arthritis Patients with Inadequate Response to Subcutaneous Injections
Russell Ross¹, Vibeke Strand², Roel Querubin³, John Goldman⁴, Richard Leff⁵, Alexis Melson¹, Pei-Ling Roerig⁶ and Alan Smith⁷, ¹Sorrento Therapeutics, Atlanta, GA, ²Stanford University, Portola Valley, CA, ³Marietta Rheumatology Associates, Marietta, GA, ⁴Northside Hospital, Atlanta, GA, ⁵Kezar Life Sciences, Chadds Ford, PA, ⁶4P Therapeutics, Orlando, FL, ⁷4P Therapeutics, Atlanta, GA
Background/Purpose: The lymphatic system serves as a conduit for transporting immune cells and inflammatory molecules present in arthritic joints to lymph nodes (LN), playing a…
Abstract Number: 0986 • ACR Convergence 2023
Medication Use Patterns and Factors Associated with Abnormal Pregnancy Outcomes in Patients with Rheumatoid Arthritis in Korea
Yeo-Jin Song¹, Soo-Kyung Cho¹, Yu-Seon Jung², Jihyun Keum³, Sun-Young Jung², Dae Hyun Yoo⁴ and Yoon-Kyoung Sung¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²College of Pharmacy, Chung-Ang University, Seoul, South Korea, ³Department of Obstetrics and Gynecology, College of Medicine, Hanyang University, Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: As female patients constitute a significant proportion of rheumatoid arthritis (RA) cases, pregnancy management is crucial for women with RA. This study aimed to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].